

1 **Visualization of Type IV-A1 CRISPR-mediated repression of gene 2 expression and plasmid replication**

3 Mariana Sanchez-Londono^{1†}, Selina Rust^{1†}, Rogelio Hernández-Tamayo^{2,3}, José Vicente
4 Gomes-Filho¹, Martin Thanbichler^{1,2,3}, and Lennart Randau^{*1,3}

5 ¹ Department of Biology, Philipps-Universität Marburg, Marburg, Germany

6 ² Max Planck Institute for Terrestrial Microbiology, Marburg, Germany

7 ³ Center for Synthetic Microbiology (SYNMIKRO), Marburg, Germany

9 * To whom correspondence should be addressed. Tel: +49 (0)6421 28 23320; Fax: +49
10 (0)6421-178 599; Email: lennart.randau@staff.uni-marburg.de

11 [†] These authors contributed equally

12 ABSTRACT

13 **Type IV CRISPR-Cas effector complexes are often encoded on plasmids and are proposed
14 to prevent the replication of competing plasmids. The Type IV-A1 CRISPR-Cas system
15 of *Pseudomonas oleovorans* additionally harbors a CRISPR RNA (crRNA) that tightly
16 regulates the transcript levels of a chromosomal target and represents a natural CRISPR
17 interference (CRISPRi) tool. This study investigates CRISPRi effects of this system using
18 synthetic crRNAs against genome and plasmid sequences. Targeting of reporter genes
19 revealed extended interference in *P. oleovorans* and *Escherichia coli* cells producing
20 recombinant CRISPR ribonucleoprotein (crRNP) complexes. RNA-Seq analyses of Type
21 IV-A1 CRISPRi-induced transcriptome alterations demonstrated highly effective long-
22 range down-regulation of histidine operon expression, whereas CRISPRi effects of dCas9
23 remained limited to the vicinity of its binding site. Single-molecule microscopy uncovered
24 the localization dynamics of crRNP complexes. The tracks of fluorescently labeled
25 crRNPs co-localized with regions of increased plasmid replication, supporting efficient
26 plasmid targeting. These results identify mechanistic principles that facilitate the
27 application of Type IV-A1 CRISPRi for the regulation of gene expression and plasmid
28 replication.**

29 MAIN

30 Microorganisms exhibit high levels of adaptability through gene transfer mechanisms
31 that include transformation, transduction, and conjugation¹. Clustered regularly interspaced
32 short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are adaptive
33 immune systems that protect prokaryotes against invading mobile genetic elements (MGEs)
34 such as viruses and plasmids^{2,3}. They are present in approximately half of all bacteria and most
35 archaea^{4,5} and are characterized by their ability to capture and incorporate fragments of foreign

36 DNA, termed protospacers, into an endogenous CRISPR array, providing a memory of past
37 encounters with MGEs. The CRISPR arrays are transcribed and processed, generating CRISPR
38 RNAs (crRNAs) that guide Cas effector proteins to recognize and interfere with
39 complementary nucleic acid sequences, thus neutralizing the invading MGEs^{5,6}. CRISPR-Cas
40 systems contain diverse Cas protein components that were used to establish a classification of
41 seven types and additional subtypes^{7,8}. The mechanisms of Type IV CRISPR-Cas systems are
42 proposed to vary and are not fully understood. Type IV systems are often found on large
43 conjugative plasmids, and subtype Type IV-A was shown to facilitate plasmid clearance and
44 gene regulation in the absence of a nuclease domain in its Cas proteins^{9–11}. The effector
45 complex of a Type IV-A CRISPR-Cas system typically consists of four proteins, including
46 Csf1 (Cas8-like), several copies of Csf2 (Cas7-like), Csf3 (Cas5-like), and Csf5/Cas6, as well
47 as a CRISPR-associated DinG (CasDinG) protein (Fig. 1a). CasDinG was identified to be
48 essential for plasmid targeting and gene silencing, as mutations that affect its helicase and
49 ATPase activities abolished CRISPR-Cas interference^{9,10,12–14}. The protein's helicase domain
50 exhibits ATP-dependent 5'-3' DNA translocase activity, enabling the unwinding of DNA and
51 RNA/DNA duplexes¹⁵. However, CasDinG was found to be dispensable for gene repression
52 when the effector complex was targeting the promoter region of a gene¹².

53 The Type IV-A1 CRISPR-Cas system of *Pseudomonas oleovorans*¹⁶ contains a crRNA
54 with a *bona fide* target in the host chromosome and its depletion was shown to increase the
55 transcript levels of the targeted *pilN* gene⁹. In contrast to most other CRISPR-Cas types, the
56 interference mechanism of Type IV-A CRISPR-Cas systems does not involve cleavage of the
57 targeted DNA. Instead, a mechanism was proposed that resembles the popular dead Cas9
58 (dCas9) tool, which was engineered to lack DNase activity. In this case, the Cas complex
59 remains tightly associated with its DNA target and is proposed to act as a “roadblock” that
60 physically obstructs bacterial polymerases, thereby inhibiting transcription elongation¹⁷. This
61 method for crRNA-guided control of gene expression was termed CRISPR interference
62 (CRISPRi).

63 The range of Type IV-A1 CRISPRi effects was not explored in detail, which hinders its
64 applications as a gene regulation tool. Therefore, this study analyzes the interference activity
65 of the Type IV-A1 CRISPR-Cas system of *P. oleovorans* in the native host and in the
66 heterologous *Escherichia coli* system. Synthetic crRNAs and RNA-Seq analyses were utilized
67 to compare regional gene repression effects of the Type IV-A1 CRISPR ribonucleoprotein
68 (crRNP) complex with those of dCas9-induced CRISPRi. In addition, single-molecule
69 microscopy was employed to elucidate the spatiotemporal dynamics of Type IV-A1 crRNP-
70 mediated DNA scanning in the presence of genomic and plasmid targets, which suggested
71 interactions with plasmid replication forks.

72

73

74

75

76 **RESULTS AND DISCUSSION**

77 **Influence of synthetic crRNAs on *sfgfp* gene expression in *P. oleovorans***

78 We previously showed that recombinant crRNP complexes can be used to target the
79 reporter gene *lacZ*, revealing CRISPRi-like activity without DNA degradation⁹. To investigate
80 this gene repression phenotype in the native host, we integrated a superfolder green fluorescent
81 protein (*sfgfp*) gene into the genome of wild-type *P. oleovorans* DSM1045. In addition, a
82 CRISPR knockout (Δ CRISPR) strain was generated which does not contain competing natural
83 crRNAs of the wild-type strain, including the self-targeting crRNA that represses expression
84 of the *pilN* gene⁹. As CasDinG was observed to be essential for Type IV-A CRISPR-Cas
85 activity^{12,15}, we also created a CasDinG knockout (Δ *dinG*) strain. Both deletion strains
86 expressed sfGFP from an arabinose inducible promoter. Additionally, they contained plasmids
87 that enabled inducible production of synthetic crRNAs compatible with the host Type IV-A1
88 crRNP. After induction, we monitored how synthetic crRNAs targeting different sites repressed
89 the expression of *sfgfp* (Fig. 1b). Negative controls included a non-targeting crRNA (C-) and a
90 distant target region located 88 kb upstream of *sfgfp*.

91 The *sfgfp* expression assays allowed us to follow long-range effects of Type IV-A1
92 CRISPR-Cas activity. In the wild-type strain, significant repression of *sfgfp* expression was
93 observed when synthetic crRNAs targeted coding or non-coding regions, including sites up to
94 3 kb up- and 1 kb downstream of *sfgfp* (Fig. 1c). A target almost 4 kb upstream of *sfgfp* showed
95 no significant reduction of the sfGFP signal and exemplifies a limit of CRISPRi effects for this
96 genomic region. These results indicate that the Type IV-A1 CRISPR-Cas system can robustly
97 interfere with gene expression across a broad genomic area and allows for a wide range of
98 possible targeting sites. The Δ CRISPR strain, which lacks all native crRNAs and has only a
99 single perfect protospacer match, also showed gene repression for an extended region with
100 reduced CRISPRi efficiency at the promoter region (Fig. 1c). In contrast, the Δ *dinG* strain only
101 showed significant downregulation of sfGFP when synthetic crRNAs targeted regions near the
102 *sfgfp* promoter. Targeting of regions distant to *sfgfp* did not exhibit significant effects on sfGFP
103 signals (Fig. 1c). Thus, we demonstrated that without CasDinG, the interference is limited to
104 regions close to the promoter, underscoring the essential role of the CasDinG helicase in
105 mediating long-distance effects.

106 Our observations support previous findings showing that (i) the Type IV-A1 system of
107 *P. oleovorans* reduces transcript levels in an extended area surrounding its native chromosomal
108 target site⁹ and that (ii) CasDinG is dispensable for targeting promoter regions¹². The extended
109 CasDinG-mediated regional effects of Type IV-A1 CRISPRi has implications for applications
110 in CRISPR-Cas-mediated gene regulation that complement dCas9-mediated CRISPRi
111 methodology^{17,18}.

112 **Comparative RNA-Seq analysis of Type IV-A1 crRNP- and dCas9-mediated CRISPRi**

113 To analyze the CRISPRi effects observed in *P. oleovorans* at single-nucleotide
114 resolution, we heterologously produced crRNP complexes in *E. coli* and analyzed their effects
115 on target gene expression by Illumina RNA-Seq. This experimental set-up enabled us to load

116 crRNPs with a single synthetic crRNA and allowed for a direct comparison with a dCas9-
117 mediated gene expression control. As a target, the histidine operon, a well-characterized
118 genome segment whose repression leads to histidine auxotrophy, was chosen¹⁹. Three key
119 target regions were studied: the promoter of the histidine operon, an internal promoter located
120 within the *hisC* gene²⁰, and the *hisA* gene (**Fig. 2a, Extended Data Fig. 1a**).

121 An analysis of the coverage plots of the different CRISPRi strains revealed striking
122 differences in the range over which the abundance of transcripts was reduced. The dCas9-
123 mediated targeting of either the coding and non-coding strand of *hisA* resulted in reduced
124 transcript levels for *hisA* and the two downstream genes *hisF* and *hisIE* (**Fig. 2b**). Transcripts
125 of the five upstream genes (*hisG* to *hisH*) were still abundant (**Extended Data Fig. 1b**). In
126 contrast, the targeting of *hisA* by the crRNP resulted in the absence of transcripts for the entire
127 operon, effectively depleting the whole histidine biosynthesis pathway. Type IV-A1 CRISPRi
128 worked successfully for crRNAs that targeted either the coding or non-coding strand of *hisA*
129 (**Fig. 2c, Extended Data Fig. 1c**). We also followed changes in the range of the affected region
130 after targeting promoters of the histidine operon. In this case, both promoter targets resulted in
131 an extended downregulation of histidine operon gene expression with transcripts of *hisB-hisIE*
132 only detectable for the construct that was guided to the main promoter of the operon. Our results
133 support the presence of an independent internal promoter in the 3' region of the *hisC* gene²⁰ as
134 the clear increase of forward read coverage are indicative of transcription initiation. Targeting
135 this internal promoter in *hisC* resulted in a positional shift of the affected region. Two genes
136 located upstream of the histidine operon and transcribed in opposite orientation were mostly
137 affected by Type IV-A1 CRISPRi targeting the main histidine operon promoter (**Fig. 2c**). The
138 CasDinG helicase is proposed to be recruited upon target DNA recognition, binds to the non-
139 target strand and initiates unwinding of DNA in 5'-3' direction¹⁵. Consequently, we propose
140 that this activity results in clashes with actively transcribing RNA polymerase while crRNPs
141 without CasDinG still prevent proper promoter recognition by the transcription machinery.

142 The downregulation of *hisA* and further genes was verified by RT-qPCR analysis (**Fig.**
143 **2d, e; Extended Data Fig. 1d, e**). Type IV-A1 CRISPR-mediated downregulation of histidine
144 operon expression resulted in a pronounced phenotype. Cells expressing crRNPs failed to grow
145 in minimal medium without the supplementation of histidine, while cells subjected to dCas9-
146 mediated CRISPRi (assaying four different spacers) were still able to grow (**Fig. 2f, Extended**
147 **Data Fig. 1f**). This suggests that the observed knock-down levels of *hisB-hisE* expression in
148 the dCas9 strain maintained sufficient histidine production. While gene expression was
149 effectively downregulated in both dCas9 and Type IV-A1 CRISPRi strains, DNA integrity was
150 always preserved (**Extended Data Fig. 2a**). A genome-wide analysis of transcript abundance
151 changes in the Type IV-A1 CRISPRi strain indicated an upregulation of genes coding for a D-
152 amino acid dehydrogenase and an alanine racemase. These genes were not affected by dCas9
153 (**Extended Data Fig. 2b, c**) and might exemplify compensatory effects of the downregulation
154 of the histidine metabolism for Type IV CRISPRi.

155 **Single-Molecule Microscopy analysis of Type IV-A1 plasmid targeting**

156 Next, we aimed to visualize Type IV-A1 interference *in vivo*. To this end, we performed
157 single-molecule microscopy (SMM) studies of individual fluorescently labelled crRNP
158 complexes to follow their movement and spatiotemporal localization within the cell.
159 Previously, we found that most crRNPs were located across the nucleoid in the presence of a
160 natural chromosomal target⁹. However, most natural Type IV protospacers are present on
161 plasmids, leading to the proposition that Type IV-A1 CRISPR-Cas systems inhibit target
162 plasmid replication¹⁰. Therefore, we introduced a high-copy conjugative plasmid in *P.*
163 *oleovorans* cells producing mNeonGreen-tagged crRNPs in order to characterize possible
164 plasmid-crRNP interactions in real time. In general, this set-up allows us to follow how far
165 molecules move from their starting point in a given time interval. This movement is expressed
166 as the jump-distance function where the probability of particle densities is classified according
167 to their displacement from the origin²¹. Thus, values closer to zero indicate a more static
168 behavior. SMM confirmed that crRNPs showed a high probability to be localized over the
169 bacterial chromosome in the wild-type strain. However, the introduction of a high-copy plasmid
170 altered the distribution of crRNPs, directing them away from the nucleoid (**Fig. 3a**).
171 Approximately one third of all crRNPs in the wild-type strain were found to exhibit a low
172 mobility with a diffusion rate of $0.023 \pm 0.001 \mu\text{m}^2 \cdot \text{s}^{-1}$, which is proposed to include crRNPs
173 associated with the native chromosomal target site. In contrast, the presence of a high-copy
174 plasmid led to a considerable decrease in this low-mobility population, accompanied by a steep
175 increase in the size of a crRNP population with an intermediate diffusion rate of 0.128 ± 0.002
176 $\mu\text{m}^2 \cdot \text{s}^{-1}$ (**Fig. 3b, Extended Data Table 1**). Given that the plasmid lacked a specific target site
177 for the native crRNP complex, this elevated diffusion rate likely represents DNA scanning
178 interactions. Therefore, in subsequent experiments, we designed plasmid targets to enable us
179 to follow plasmid interference.

180
181 Monitoring the behavior of plasmid-targeting crRNPs is challenging as their activity
182 inhibits target plasmid replication. To achieve this goal, we generated recombinant *E. coli*
183 BL21-AI cells that produced Type IV-A1 crRNPs, whose large subunit (*cfs1*) was tagged with
184 mNeonGreen, using the basal activity of the T7 promoter in the absence of inducer. Genomic
185 *lacZ* targeting combined with blue-white screening^{9,22} was applied to verify that the fusion with
186 the fluorescent tag did not affect Type IV-A1 CRISPR-Cas interference (**Extended Data Fig.**
187 **3a**). We then used the *E. coli* BL21-AI transformants to analyze the diffusional behavior of the
188 fluorescent crRNPs when targeting a plasmid or *lacZ* (**Fig. 3c**). After introduction of the
189 respective target or non-target plasmid via electroporation, the cells were allowed to recover
190 for 30 min prior to SMM analysis. This time frame was estimated to be appropriate for the
191 synthesis and maturation of fluorescent proteins²³. The results supported our observations in
192 the native host and revealed that in the presence of a plasmid containing the target sequence,
193 crRNPs were redistributed to cellular regions located outside of the nucleoid, especially
194 towards polar regions (**Fig. 3d, Extended Data Fig. 3b, c**).

195 Quantification of fluorescent particles revealed 58 to 83 recombinant crRNPs in cells
196 with different targets (**Extended Data Fig. 3d and Table 2**), exceeding the previously reported
197 average of 26 crRNPs per cell in the native system⁹. We calculated the Mean Squared
198 Displacement (MSD) as the average squared distance that crRNPs travel over time to analyze

199 their diffusion behavior. This analysis revealed a lower mobility of Type IV-A1 complexes, as
200 indicated by a decrease in the MSD and diffusion rates, when a genome target was present (**Fig.**
201 **3e; Extended Data Fig. 3e; Extended Data Table 3**). The low-mobility crRNP population
202 increased even further in the presence of a target on the plasmid (**Fig. 3e**), and the distribution
203 of the tracks suggests a greater likelihood of encountering replicating high-copy plasmids in
204 the polar regions of the bacterial cell.

205
206 **Type IV-A1 CRISPR-Cas complexes interfere with plasmid replication.**

207 The relocation of crRNPs in response to the presence of plasmids suggests that they
208 possibly interact with components involved in plasmid replication. One potential interactor is
209 DnaX, an essential component of the clamp loader complex in the DNA replisome²⁴. Earlier
210 studies demonstrated that a decrease in the diffusion rate of fluorescently labeled DnaX
211 indicates stalled replication forks²⁵. We therefore analyzed whether the dynamics of DnaX were
212 affected by crRNPs in the presence of plasmid targets. To this end, we generated an *E. coli*
213 BL21-AI derivative whose endogenous *dnaX* gene was fused to the gene for the fluorescent
214 protein mScarlet (mS). The resulting strain BL21-AI:*dnaX-mS* was then used to track DnaX-mS
215 in the presence of the mNeonGreen-tagged crRNPs after the introduction of a non-target or
216 target plasmid (**Fig. 4a**). In cells with non-target plasmid, DnaX-mS tracks were localized
217 diffused over the chromosome (**Fig. 4b**). The fusion protein showed considerable mobility, as
218 reflected by a high MSD (**Fig. 4c**) and a large fraction of molecules in the mobile population
219 (**Fig. 4d**). Cells harboring a plasmid targeted by the crRNPs, by contrast, showed a distinct
220 change in the localization pattern of DnaX-mS (**Fig. 4b; Extended Data Fig. 4a, b**),
221 accompanied by a substantial decrease in the MSD (**Fig. 4c**) and the diffusion rate of DnaX-mS,
222 with a steep increase in the proportion of molecules with low and intermediate mobility
223 and a strong decrease of the mobile population (**Fig. 4d, Extended Data Table 4**).

224 The marked reduction in the diffusion rate of DnaX-mS in the presence of a target
225 plasmid could be the result of replication fork stalling due to a Type IV crRNP roadblock²⁶.
226 Similar effects have been observed for Type I interference complexes which can block DNA
227 replication²⁷.

228 To further investigate the interaction between DnaX and crRNPs, we analyzed the
229 trajectories of crRNPs for their spatial proximity to active replication forks. We defined active
230 replication forks as distinct foci of DnaX-mS, because DnaX is presumed to condense on
231 replisomes when actively engaged in replication and to adopt a diffuse localization when
232 replication ceases²⁸. This analysis revealed that crRNPs localized to the proximity of replication
233 forks in both the presence and absence of a target plasmid. Notably, a particularly close
234 proximity to replication forks was observed when the cell harbored a target plasmid (**Fig. 4e**).

235 **CONCLUSION**

236 In conclusion, Type IV-A1 CRISPR-Cas activity was visualized at the transcriptome
237 and cell biological level. The transcriptomics analyses highlighted long-range gene repression
238 effects that rely on the processivity of the CasDinG helicase. CasDinG may initiate the
239 unwinding of the non-target DNA strand upon target recognition, potentially encountering and
240 stalling RNA polymerases. We also showed that CasDinG is not required for Type IV-A1
241 activity if its target is a promoter sequence. Consistent with recently reported similar
242 observations¹², this observation indicates that the crRNP is able to inhibit transcription
243 initiation. Together, our findings suggest a transcription-dependent role of CasDinG in
244 modulating Type IV-A CRISPR-Cas activity.

245 Native Type IV-A1 CRISPR-Cas systems most often contain spacers against plasmid
246 targets. Our SMM analysis supports this preference for plasmid targets as evidenced by (i) the
247 reduced diffusion rate of crRNPs if plasmid targets were provided and (ii) the polar
248 redistribution of crRNPs in the presence of high-copy plasmids. CasDinG is likely recruited to
249 the target, and it remains to be investigated if this helicase leaves the crRNPs to translocate
250 along the DNA or reels in DNA while remaining attached to the complex.

251 While dCas9 serves as a highly popular engineered tool to inhibit the activity of RNA
252 polymerases¹⁷, it appears to be less efficient than Type IV-A1 in the downregulation of gene
253 clusters or operon regions. In this study, the Type IV-A1 CRISPR-Cas system was found to
254 serve as a versatile and effective tool to stimulate CRISPRi activities that resemble gene
255 knockouts without actual degradation of the target DNA. Notably, the existence of alternative
256 promoters represents a significant challenge for CRISPRi, while Type IV-A1 activity still
257 achieves an efficient downregulation of extended gene clusters with multiple promoters. This
258 highlights the potential of Type IV-A1 CRISPRi for operon regulation.

259 **MATERIALS AND METHODS**

260 **Strains and growth conditions**

261 *E. coli* BL21-AI and *P. oleovorans* DSM 1045 cells were cultivated in LB media at
262 37°C, optionally supplemented with antibiotic(s). *E. coli* WM3064 cultures were grown at 37°C
263 in LB media supplemented with diaminopimelic acid (DAP) (**Extended Data Table 6**).

264 **Generation of *P. oleovorans* gene knock-in and knock-out strains**

265 The insertion of the *sfgfp* reporter construct and the deletion of the CRISPR array or
266 *dinG* in the chromosome of *P. oleovorans* were carried out following the adapted protocols for
267 endonucleases-mediated recombination^{29,30}. Derivatives of the suicide vector pEMG were used
268 to deliver genome-specific sequences flanking the region of interest. ~500 bp flanks of a
269 homologous region up- and downstream of the insertion (or deletion) site were used. The region
270 chosen for the insertion of *sfgfp* insertion is located in between the *tadA* and *mltF* genes, as the
271 integration of a gene in this specific region had no effect on growth in *Pseudomonas putida*³¹.
272 The helper plasmid pSEVA6213S was used for digestion of the suicide vector pEMG, followed

273 by a plasmid curing assay. For the deletion of *csf4* (CasDinG) of the Type IV-A1 CRISPR-Cas
274 system of *P. oleovorans*, ~500 bp of homologous regions up- and downstream of *csf4* were
275 cloned into the pEMG suicide vector between its BamHI and EcoRI restriction sites. To delete
276 the CRISPR array, two fragments of ~500 bp of homologous regions up- and downstream of
277 the CRISPR array were cloned into the pEMG vector between the BamHI and EcoRI restriction
278 sites. A list of the plasmids used in this work is provided in the (**Extended data Table 5**).
279

280 CRISPR interference (CRISPRi) assays in *P. oleovorans*

281 Derivatives of the pSEVA424 vector (**Extended data Table 5**) were transferred by
282 conjugation into different *sfgfp*-expressing *P. oleovorans* (wild type, Δ CRISPR and Δ *dinG*)
283 strains. The plasmids carry an *araC* gene and different crRNAs, inducible with IPTG, that target
284 different chromosomal regions in the *sfgfp*-expressing *P. oleovorans* strains (**Extended data**
285 **Table 6**). For crRNA induction, IPTG was added to the cells to a final concentration of 1 mM.
286 For the induction of *sfgfp*, arabinose was added to a final concentration of 0.5% (w/v). Cells
287 were grown in a 96-well plate shaking (180 rpm) at 37°C. Growth and fluorescence were
288 monitored for 48 hours using a Magellan™ Infinite® 200 Pro plate reader, measuring the
289 optical density at 600 nm (OD₆₀₀) and the fluorescence of sfGFP, with excitation at 485 nm and
290 detection of the emission at 510 nm. Data were further processed using RStudio³².
291

292 Generation of BL21-AI mutants

293 To tag the C-terminal domain of DnaX, we integrated the gene for the fluorescent
294 protein mScarlet at the chromosomal *dnaX* locus of *E. coli* BL21-AI following the protocol by
295 Thomason et al.³³. To this end, cells were transformed by electroporation with linear DNA
296 containing the mScarlet gene sequence flanked by 50 nt of homologous sequences upstream
297 and downstream of the desired integration site (**Extended Data Table 6**). Successful insertion
298 of the *mScarlet* sequence was confirmed by PCR using primers flanking the insertion site, and
299 the integration was further verified through Sanger sequencing.
300

301 CRISPR interference (CRISPRi) assays in *E. coli*

302 **Genomic auxotroph targets.** Genes in the histidine operon in *E. coli* strain BL21-AI
303 were used as targets for the CRISPRi experiment comparing the recombinant Type IV-A1
304 CRISPR-Cas of *P. oleovorans* with the dCas9 system. An all-in-one plasmid system was used
305 to express either the Type IV-A1 crRNP complex (pSR77) or dCas9 (pMSL26) (**Extended**
306 **data Table 5**). The respective vectors carrying editable spacers without potential targets, were
307 used as negative controls in all the experiments. Protospacers were chosen in the region of the
308 targeted gene containing a 5'-AAG-3' PAM and 5'-NGG-3' PAM for Type IV-A1 and dCas9
309 treatments, respectively (**Extended data Table 7**). Colonies obtained right after transformation
310 were grown overnight in LB media at 37°C. The cells were diluted into fresh medium and
311 cultivated for 6 hours in LB medium supplemented with 1 mM IPTG and 0.2% (w/v) arabinose.
312 Then, 2 ml of the culture were pelleted at 9000 rpm for 3 min, and cells were washed twice
313 with completed M9 minimal medium (commercially available) supplemented with 2 mM
314 MgSO₄, 0.1 mM CaCl₂, 0.4% (w/v) glucose and corresponding antibiotics to remove remaining
315 LB. Cells were plated for spotting assays onto completed M9 minimal media agar plates
316 (additionally supplemented with 1 mM IPTG and 0.2% (w/v) arabinose and with/without

317 supplementation of 0.6 mM histidine). OD₆₀₀ was normalized to 1 for all treatments, followed
318 by 10-fold serial dilutions. The remaining volume of cells were flash-frozen for RNA
319 extraction.

320

321 **Genomic targeting of *lacZ* for SMM.** CRISPRi assays were also carried out with cells
322 containing the recombinant Type IV-A1 CRISPR-Cas system targeting genomic *lacZ* and used
323 for the single-molecule microscopy (SMM) studies to corroborate the interference activity of
324 the complex visualized in the different SMM experiments. To this end, the genes of all Type
325 IV-A1 Cas proteins and DinG were cloned into a pETDuet-1 vector. Then, an allele encoding
326 a Csf1-mNeonGreen fusion protein with a GSGSGS linker was cloned into the resulting
327 plasmid (pMSL66). This vector was co-transformed with a pCDFDuet-1 vector containing a
328 minimal CRISPR array with a spacer targeting *lacZ* or a filler spacer as a negative control into
329 BL21-AI:*dnaXmS* cells (**Extended data Table 5**). Single colonies obtained right after
330 transformation were grown overnight in LB media with the respective antibiotics. After 16
331 hours of growth, fresh cultures with a starting OD₆₀₀ of 0.1 were regrown to an OD₆₀₀ of 0.6.
332 Then, 1 ml of cells was pelleted and resuspended in 1 ml of ddH₂O for microscopic analysis.
333 A small sample was also plated onto LB agar plates containing 0.005% (w/v) X-gal, 0.2% (w/v)
334 arabinose, 1 mM IPTG and suitable antibiotics for blue-white screening.

335

336 **Plasmid interference assay for SMM.** BL21-AI:*dnaXmS* cells were transformed with
337 the two-plasmid system encoding the Type IV-A1 crRNP complex. For this experiment, the
338 spacer in the pCDF-Duet vector was designed to target a protospacer with a 5'-AAG-3' PAM
339 in a third plasmid once introduced by electroporation. Colonies obtained right after
340 transformation were grown overnight and then used for the preparation of electrocompetent
341 cells following a protocol adapted from Lessard et al.³⁴. To this end, 20 ml of fresh culture was
342 grown to an OD₆₀₀ of 0.6. Cells were pelleted at 4600 rpm for 7 min at 4°C and washed with
343 20 ml of cold sterile ddH₂O and pelleted again. After resuspension in 1 ml of cold sterile
344 ddH₂O, a last centrifugation was carried out at 13000 rpm for 1 min at 4°C. Cells were
345 resuspended in 200 µl of cold sterile ddH₂O. For every electroporation, 50 µl of cells were
346 mixed with 10 ng of the third plasmid, and cells were exposed to one pulse at 1.8 kV, 25 µF
347 and 200 Ω in a Micropulser electroporator (Biorad). Cells were immediately resuspended in
348 550 µl of LB and recovered at 37°C for 30 minutes at 450 rpm. Cells were pelleted and
349 resuspended in 1ml of ddH₂O, and 2 µl were used as samples for single-molecule microscopy.

350

351 **Single-Molecule Microscopy (SMM) in the recombinant and native system.**

352 Single-molecule microscopy (SMM) experiments were performed on an automated
353 Nikon Ti2-Eclipse microscope equipped with an Abbelight SAFe 180 3D nanoscopy module
354 with appropriate dichroic filters (ET488/ET561/75 bandpass, Croma) and a Nikon CFI Apo
355 TIRFx100 oil objective (NA 1.49). All lasers (488 Oxxius, 561 Oxxius) were combined into a
356 single output via an Oxxius L4Cc combiner. Fluorescence was detected with an ORCA-
357 Flash4.0 V3 EMCCD camera (Hamamatsu Photonics), using a pixel size of 512 nm, frame
358 transfer mode and the following readout parameter settings: EM-gain 300, pre-amp gain 2 and
359 30 MHz readout speed. The imaging process was controlled using NEO SAFe software
360 (Abbelight). Single-particle tracks were recorded using slimfield microscopy³⁵. In this

361 approach, the back aperture of the objective is underfilled by illumination with a collimated
362 laser beam of reduced width, generating an area of $\sim 10 \mu\text{m}$ in diameter with a light intensity
363 high enough to enable the visualization of single fluorescent protein molecules at very high
364 acquisition rates. Images were taken continuously during laser excitation. The single-molecule
365 level was reached by bleaching most mNeonGreen molecules in the cell for 100 to 500 frames,
366 followed by tracking of the remaining molecules. To perform the SMM analysis of BL21-
367 AI:*dnaXmS* cells carrying plasmids pMSL66 and pSR24 and transformed with target or no-
368 target plasmid, 3000 frames were recorded at a frame rate of 30 ms, with a camera sensor size
369 of 256 pixels and HILO illumination. First, mScarlet was tracked over 1000 frames using 5.2%
370 laser power and an ET561 filter set. After a gap of 500 frames of gap, mNeonGreen was tracked
371 over 1500 frames using 10% laser power and an ET488 filter set). A total of 8-10 movies were
372 analyzed per condition from two independent colonies. The SMM analysis of the native *P.*
373 *oleovorans* system in the presence of a high-copy plasmid was carried out as described
374 previously⁹.

375

376 SMM data processing and diffusion analysis of single-molecule tracks

377 To analyze the SMM data, the cell meshes were determined with Oufti 1.2³⁶. Bleaching
378 curves were analyzed in ImageJ 2.0³⁷ to verify single molecule observations. An estimate of
379 the diffusion coefficient and insight into the kind of diffusive motion exhibited were obtained
380 from mean-squared-displacement (MSD)-versus-time-lag curves. In addition, the frame-to-
381 frame displacements of all molecules in x and the y direction were fitted to a two-population
382 Gaussian mixture model to determine the proportions of mobile and static molecules in each
383 condition, a widely accepted method to analyze the diffusive behavior of molecules. This
384 provides an estimate of the diffusion coefficient as well as of the kind of motion. To identify
385 molecule populations with distinct mobilities, we compared the frame-to-frame displacement
386 of all molecules in x and the y directions. Tracking analysis was performed with U-track-2.2.0³⁸
387 in the Matlab environment (MathWorks, Natick, MA, USA), using a minimum length of five
388 steps. Finally, the diffusion rates were calculated according to $D_i = \sigma^2 / 2\Delta t$, ($i=1,2,3$), where
389 Δt is the time interval between subsequent imaging frames. The generation of trajectory maps
390 and the visualization of static and the mobile tracks in a standardized cell are based on the
391 Matlab script SMTracker 2.0²¹.

392

393 Distance probability measurement of Type IV-A1 regarding DnaX-mScarlet foci

394 In this study, dwelling tracks representing movements of slow-population DnaX-
395 mScarlet molecules were plotted for each cell analyzed. The resulting movies were saved as
396 TIFF images within the same folder containing data related to Type IV-A1-mNeonGreen
397 tracks. Using the distance measurement tool provided by SMTracker 2.0, all foci from the
398 DnaX-mScarlet dwelling images were used as reference points. After plotting the tracks from
399 the three populations of the mNeonGreen-tagged crRNPs onto each cell, we measured their
400 distances from the nearest DnaX-mScarlet focus. To this end, we identified the five points in
401 the track that represented the positions of the molecule at different times. We then specified a
402 single point in the center of the focus as a fixed reference position and calculated the distance
403 from this point for each of the five points in the track, using the distance formula

404 $D = \sqrt{(x_{focus} - x_i)^2 + (y_{focus} - y_i)^2}$, where (x_{focus}, y_{focus}) are the coordinates of the focus
405 point and (x_i, y_i) are the coordinates of the point at position i in the track. To further characterize
406 the movement of the molecule relative to the focus point. Histograms were then generated to
407 plot the probability distribution of molecule trajectories based on their proximity to the nearest
408 focus.

409

410 **RNA extraction**

411 Total RNA was extracted using TRIzol from pellets previously treated with 0.8 ml of
412 lysis buffer (2% SDS and 4 mM EDTA) and heated for 2 min at 90°C. Total RNA was purified
413 using Acid-Phenol:Chloroform (Invitrogen) extraction. The extracted RNA was treated with
414 DNase I (NEB) and purified with the Monarch RNA clean-up kit (NEB). cDNA was prepared
415 from 1 µg of RNA, using SuperScript II Reverse Transcriptase (Invitrogen) according to the
416 manufacturer's instructions.

417

418 **RT-qPCR**

419 RT-qPCR was performed following a previously described protocol⁹ with primers
420 against *lacZ*, *hisA*, *hisH*, *hisF*, and *recA* as the housekeeping gene control in *E. coli* BL21-AI.
421 Primers are listed in **(Extended data Table 8)**.

422

423 **Illumina RNA sequencing and data analysis**

424 RNA quality and integrity was inspected in 1% agarose gels and a 2100 Bioanalyzer
425 (Agilent). rRNA depletion, library preparation, and sequencing (Illumina Nova Seq X - Paired
426 End Mode – 150 nt reads) were performed by Novogene, Inc. Data quality was assessed using
427 FastQC (v0.11.9)³⁹, reads were trimmed with Cutadapt (v3.5)⁴⁰ and aligned to the *Escherichia*
428 *coli* BL21-AI (CP047231.1) genome using Hisat2 (v2.2.1)⁴¹. Output files were converted and
429 sorted using samtools suite (v1.13)⁴² and mapped reads were inspected using IGV (v2.16.2)⁴³.
430 Differential expression analysis was performed with the R package DESeq2 (v1.42.1)⁴⁴ and
431 coverage plots were generated using ggplot2 (v3.5.0)⁴⁵.

432

433 **Statistics and Reproducibility**

434 CRISPRi assays, RT-qPCR and RNA-seq were performed in triplicate ($n = 3$
435 independent biological replicates, based on 3 different colonies). All attempts to replicate the
436 experiments were successful. Statistical analyses and the determination of p-values for the RT-
437 qPCR experiments were performed with an unpaired two-sided t-test.

438

439 **Data availability**

440 All data are available in the manuscript or the Extended data file. Raw data from RNA-
441 seq is available at the European Nucleotide Archive (ENA) under the accession code
442 PRJEB74190. Raw data from single molecule microscopy analyses are provided at
443 <https://doi.org/10.6084/m9.figshare.25913251>. Source data are provided with this paper.

444

445

446

447 **Acknowledgements**

448 This work was supported by the Priority Research Program (Project number
449 360987069) of the German Research Foundation (DFG) to L.R. and the Max Planck Society
450 (Max Planck Fellowship to M.T.). We thank the CNV Stiftung for supporting M.S.-L.

451

452 **Author contributions**

453 M.S.-L. and S.R. performed Type IV-A1 CRISPR-Cas activity assays. M.S.-L.
454 performed qRT-PCR analyses. S.R. performed CRISPRi assays in *P. oleovorans*. M.S.-L. and
455 R.H.-T. conceived, performed and analyzed fluorescence microscopy studies. J.V.G.-F.
456 analyzed the RNA-seq data. M.T. contributed to the conceptualization of the single-molecule
457 microscopy experiments and revised the manuscript. L.R., M.S.-L. and S.R. conceived the
458 experiments. L.R. and M.T. acquired funding for this study. L.R. and M.T. supervised the
459 study. L.R., M.S.-L. and S.R. wrote the manuscript, with the support from all other authors.


460

461 **Competing interests**

462 The authors declare no competing interests.

463 **FIGURES**

464
465
a




466
467
468
469
470
471
472
473
474
475

Figure 1. Regional effects of Type IV-A1 CRISPR-Cas activity in *P. oleovorans*. **a)** Schematic representation of Type IV-A1 CRISPR-Cas endogenously expressed in *P. oleovorans*. **b)** Schematic representation of target sites. Triangles represent locations of protospacers on template (white) and non-template strand (black). **c)** Different sfGFP expressing *P. oleovorans* strains were transformed with plasmids encoding synthetic crRNAs that target protospacers in different regions (see **b**). A non-targeting crRNA served as a negative control (C+). Data represent the mean (+SD) of 3 independent experiments. The statistical significance (*p*-value) of differences to the results obtained for target 1 were calculated using an unpaired, two-tailed t-test (* *p*<0.05, ** *p*<0.01, *** *p*<0.001, **** *p*<0.0001).

476

Figure 2



477 **Figure 2. Interference of the recombinant Type IV-A1 CRISPR-Cas system on the histidine operon. a.**
478 Schematic representation of a 17 kb region of *E. coli* BI21-A1 genome containing the histidine operon. Genes are
479 represented as horizontal arrows indicating the direction of transcription. Green arrows represent genes outside of
480 the histidine operon, and salmon arrows represent genes that are part of the histidine operon. Gene A: *plaP*, B:
481 *yoel*, C: GSU80_09680, D: GSU80_09685, F: *wzzB*, G: GSU80_09740, H: *gndA* and I: *opsG*. Vertical arrows (1, 2,
482 and 3) indicate three target sites, targeting the coding or non-coding strand, respectively. 1: Target in histidine
483 operon promoter, 2: Target in internal promoter in *hisC*, and 3: Target in *hisA*. **b.** Illumina RNA-Seq coverage plots
484 of the histidine operon region with dCas9 targeting *hisA* gene (3). The plots indicate a reduction in the number of
485 reads in the local area of the target in comparison to the negative control (dCas9 C-). **c.** Illumina RNA-Seq coverage
486 plots of the histidine operon region with different sites targeted by the Type IV-A1 CRISPR-Cas system. The plots
487 indicate a significant reduction in the number of reads for the different treatments in comparison to the negative
488 control (IV-A1 C-). **d.** RT-qPCR of *hisA* targeted by dCas9 (3). **e.** RT-qPCR of *hisA* with different Type IV-A1 target
489 sites on the histidine operon. Statistical analysis was performed using an unpaired two-tailed t-test. Data represent
490 the mean (\pm SD) of n=3 biological replicates), with *** p \leq 0.0005 and **** p < 0.0001. **f.** Spotting assay after
491 CRISPRi with different sites targeted by dCas9 or Type IV-A1. Cells were plated in 10-fold dilution series (3 μ l of
492 each dilution) onto two plates made of M9 minimal medium with or without 0.06 mM histidine, respectively, both
493 containing inducers (1 mM IPTG and 0.2% (w/v) arabinose).

Figure 3





Figure 3. Spatiotemporal dynamics of Type IV-A1 crRNP complexes targeting the genome or plasmids, studied by SMM in the native and a recombinant system. **a.** Heat maps showing the probability of distribution of all tracks detected in a representative cell. The plots give the spatial distribution of the mNeonGreen-tagged Type IV-A1 crRNP complex of *P. oleovorans* in the wild-type strain and the wild type harboring a high-copy plasmid. Areas with darker coloration indicate a higher concentration of tracks, reflecting longer scanning times. **b.** Jump-distance distribution histograms for mNeonGreen-tagged Type IV-A1 complexes in *P. oleovorans* showing the probability of displacement in the wild-type strain and the wild type harboring a high-copy plasmid. The y-axis represents the probability density, indicating how frequently a molecule travels a certain distance in one step plotted on the x-axis in micrometers (μm). The closer the values are to zero, the more static the molecules are. The model was fitted assuming three populations of complexes with distinct diffusion behavior. Salmon curves show slow populations, green curves show the intermediate population, and dark grey curves show the mobile population. Global diffusion constants were used to facilitate the comparison of the diffusion behaviors in different conditions. Insets: bubble plots obtained by squared displacement analyses (SQD), showing the population sizes and diffusion constants (y-axis) of the three populations. Each plot is accompanied by the respective residuals, whose size (between ± 0.02) verifies the statistical significance of the results. **c.** Schematic of the different strains used to study the diffusion dynamics of *P. oleovorans* crRNP complexes in the heterologous host *E. coli*. Parental strains containing two plasmids (one expressing the mNeonGreen-tagged Type IV-A1 crRNP and one carrying the minimal CRISPR array with the spacer) were electroporated with either a non-target plasmid, a target plasmid, or nuclease-

free water, depending on the assay condition. The target is represented as a small reddish circle located either on the chromosome or a plasmid. **d.** Heat maps showing the probability distribution of all tracks detected in a representative cell for each of the indicated strains. The heat maps give the spatial distribution of mNeonGreen-tagged Type IV-A1 crRNP complexes heterologously expressed in *E. coli* BL21-A1:*dnXmS*. Areas with darker coloring indicate a higher concentration of tracks, reflecting longer scanning times. **e.** Jump-distance distribution plots showing the diffusion behavior of mNeonGreen-tagged crRNP complexes in the three indicated recombinant strains.

Figure 4



494
495
496
497
498
499
500
501
502
503
504
505
506

Figure 4. Spatiotemporal dynamics of DnaX-mS with and without Type IV-A1 crRNPs targeting plasmids. **a.** Schematic of the strains used to study the dynamics of DnaX. **b.** Heat maps of all tracks projected in a representative cell indicating the spatial distribution of mScarlet-tagged DnaX (DnaX-mS) in *E. coli* BL21-A1 described in panel a. The yellow-reddish areas indicate the highest probability of distribution tracks with longer scanning time. **c.** Mean Square Displacement (MSD) analysis of DnaX-mS molecules in cells expressing mNeonGreen-tagged crRNPs with and without plasmid target. Shown is a comparison of the MSD values obtained at different time intervals in the two conditions. The data points represent the mean MSD, with error bars indicating the standard error of the mean (SEM). **d.** Jump-distance distribution histograms of the DnaX-mS molecules in the two indicated conditions were calculated as described in figure 3e. **e.** Histogram showing the probability distribution of distance measurements between mNeonGreen-tagged crRNP complex tracks and the nearest DnaX focus, representing dwelling events. Green bars indicate Type IV-A1-mNeonGreen tracks in the presence of a target plasmid. Salmon bars represent the Type IV-A1-mNeonGreen tracks in the presence of a non-target plasmid.

507 REFERENCES

- 508 1. Burrus, V. & Waldor, M. K. Shaping bacterial genomes with integrative and conjugative elements.
509 *Research in Microbiology* **155**, 376–386; 10.1016/j.resmic.2004.01.012 (2004).
- 510 2. Frost, L. S., Leplae, R., Summers, A. O. & Toussaint, A. Mobile genetic elements: The agents of
511 open source evolution. *Nature Reviews Microbiology* **3**, 722–732; 10.1038/nrmicro1235 (2005).
- 512 3. Barrangou, R. *et al.* CRISPR provides acquired resistance against viruses in prokaryotes.
513 *Science* **315**, 1709–1712; 10.1126/science.1138140 (2007).
- 514 4. Brouns, S. J. J. *et al.* Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science* **321**,
515 960–964; 10.1126/science.1159689 (2008).
- 516 5. Sorek, R., Kunin, V. & Hugenholtz, P. CRISPR-a widespread system that provides acquired
517 resistance against phages in bacteria and archaea. *Nature Reviews Microbiology* **6**, 181–186;
518 10.1038/nrmicro1793 (2008).
- 519 6. Horvath, P. & Barrangou, R. CRISPR/Cas, the immune system of bacteria and archaea. *Science*
520 **327**, 167–170; 10.1126/science.1179555 (2010).
- 521 7. Makarova, K. S. *et al.* Evolution and classification of the CRISPR-Cas systems. *Nature Reviews
522 Microbiology* **9**, 467–477; 10.1038/nrmicro2577 (2011).
- 523 8. Makarova, K. S. *et al.* An updated evolutionary classification of CRISPR-Cas systems. *Nature
524 Reviews Microbiology* **13**, 722–736; 10.1038/nrmicro3569 (2015).
- 525 9. Guo, X. *et al.* Characterization of the self-targeting Type IV CRISPR interference system in
526 *Pseudomonas oleovorans*. *Nature Microbiology* **7**, 1870–1878; 10.1038/s41564-022-01229-2
527 (2022).
- 528 10. Pinilla-Redondo, R. *et al.* Type IV CRISPR-Cas systems are highly diverse and involved in
529 competition between plasmids. *Nucleic Acids Research* **48**, 2000–2012; 10.1093/nar/gkz1197
530 (2020).
- 531 11. Crowley, V. M. *et al.* A Type IV-A CRISPR-Cas system in *Pseudomonas aeruginosa* mediates
532 RNA-guided plasmid interference *in vivo*. *The CRISPR journal* **2**, 434–440;
533 10.1089/crispr.2019.0048 (2019).
- 534 12. Benz, F. *et al.* Type IV-A3 CRISPR-Cas systems drive inter-plasmid conflicts by acquiring
535 spacers in trans. *Cell Host & Microbe*; 10.1016/j.chom.2024.04.016 (2024).
- 536 13. Cui, N. *et al.* Type IV-A CRISPR-Csf complex: Assembly, dsDNA targeting, and CasDinG
537 recruitment. *Molecular Cell* **83**, 2493-2508.e5; 10.1016/j.molcel.2023.05.036 (2023).
- 538 14. Koonin, E. V. & Makarova, K. S. Mobile Genetic Elements and Evolution of CRISPR-Cas
539 Systems: All the Way There and Back. *Genome Biology and Evolution* **9**, 2812–2825;
540 10.1093/gbe/evx192 (2017).
- 541 15. Domgaard, H. *et al.* CasDinG is a 5'-3' dsDNA and RNA/DNA helicase with three accessory
542 domains essential for Type IV CRISPR immunity. *Nucleic Acids Research* **51**, 8115–8132;
543 10.1093/nar/gkad546 (2023).
- 544 16. Lee, M. & Chandler, A. C. A study of the nature, growth and control of bacteria in cutting
545 compounds. *Journal of Bacteriology* **41**, 373–386; 10.1128/jb.41.3.373-386.1941 (1941).
- 546 17. Qi, L. S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of
547 gene expression. *Cell* **152**, 1173–1183; 10.1016/j.cell.2013.02.022 (2013).
- 548 18. Gilbert, L. A. *et al.* CRISPR-mediated modular RNA-guided regulation of transcription in
549 eukaryotes. *Cell* **154**, 442–451; 10.1016/j.cell.2013.06.044 (2013).

550 19. Alifano, P. *et al.* Histidine biosynthetic pathway and genes: structure, regulation, and evolution. *Microbiological Reviews* **60**, 44–69; 10.1128/mr.60.1.44-69.1996 (1996).

551 20. Thomason, M. K. *et al.* Global transcriptional start site mapping using differential RNA sequencing reveals novel antisense RNAs in *Escherichia coli*. *Journal of Bacteriology* **197**, 18–28; 10.1128/JB.02096-14 (2015).

552 21. Oviedo-Bocanegra, L. M., Hinrichs, R., Rotter, D. A. O., Dersch, S. & Graumann, P. L. Single molecule/particle tracking analysis program SMTracker 2.0 reveals different dynamics of proteins within the RNA degradosome complex in *Bacillus subtilis*. *Nucleic Acids Research* **49**, e112; 10.1093/nar/gkab696 (2021).

553 22. Csörgő, B. *et al.* A compact Cascade-Cas3 system for targeted genome engineering. *Nature Methods* **17**, 1183–1190; 10.1038/s41592-020-00980-w (2020).

554 23. Khmelinskii, A. *et al.* Tandem fluorescent protein timers for in vivo analysis of protein dynamics. *Nature Biotechnology* **30**, 708–714; 10.1038/nbt.2281 (2012).

555 24. Onrust, R. *et al.* Assembly of a chromosomal replication machine: Two DNA polymerases, a clamp loader, and sliding clamps in one holoenzyme particle. I. Organization of the clamp loader. *Journal of Biological Chemistry* **270**, 13348–13357; 10.1074/jbc.270.22.13348 (1995).

556 25. Hernández-Tamayo, R. & Graumann, P. L. *Bacillus subtilis* RarA forms damage-inducible foci that scan the entire cell. *BMC Research Notes* **12**, 219; 10.1186/s13104-019-4252-x (2019).

557 26. Whinn, K. S. *et al.* Single-molecule visualization of stalled replication-fork rescue by the *Escherichia coli* Rep helicase. *Nucleic Acids Research* **51**, 3307–3326; 10.1093/nar/gkad186 (2023).

558 27. Killelea, T., Hawkins, M., Howard, J. L., McGlynn, P. & Bolt, E. L. DNA replication roadblocks caused by Cascade interference complexes are alleviated by RecG DNA repair helicase. *RNA Biology* **16**, 543–548; 10.1080/15476286.2018.1496773 (2019).

559 28. Reyes-Lamothe, R. *et al.* High-copy bacterial plasmids diffuse in the nucleoid-free space, replicate stochastically and are randomly partitioned at cell division. *Nucleic Acids Research* **42**, 1042–1051; 10.1093/nar/gkt918 (2014).

560 29. Wirth, N. T., Kozaeva, E. & Nikel, P. I. Accelerated genome engineering of *Pseudomonas putida* by I-SceI-mediated recombination and CRISPR-Cas9 counterselection. *Microbial Biotechnology* **13**, 233–249; 10.1111/1751-7915.13396 (2020).

561 30. Hmelo, L. R. *et al.* Precision-engineering the *Pseudomonas aeruginosa* genome with two-step allelic exchange. *Nature Protocols* **10**, 1820–1841; 10.1038/nprot.2015.115 (2015).

562 31. Chaves, J. E. *et al.* Evaluation of chromosomal insertion loci in the *Pseudomonas putida* KT2440 genome for predictable biosystems design. *Metabolic Engineering Communications* **11**, e00139; 10.1016/j.mec.2020.e00139 (2020).

563 32. Posit team. *RStudio: Integrated Development Environment for R*. (Posit Software, PBC, Boston, MA, 2024).

564 33. Thomason, L. C., Costantino, N. & Court, D. L. *E. coli* genome manipulation by P1 transduction. *Current Protocols in Molecular Biology* **79**, 1.17.1-1.17.8; 10.1002/0471142727.mb0117s79 (2007).

565 34. Lessard, J. C. Transformation of *E. coli* via electroporation. *Methods in Enzymology* **529**, 321–327; 10.1016/B978-0-12-418687-3.00027-6 (2013).

566 35. Plank, M., Wadhams, G. H. & Leake, M. C. Millisecond timescale slimfield imaging and automated quantification of single fluorescent protein molecules for use in probing complex

594 biological processes. *Integrative Biology: Quantitative Biosciences from Nano to Macro* **1**, 602–
595 612; 10.1039/b907837a (2009).

596 36. Paintdakhi, A. *et al.* Oufti: an integrated software package for high-accuracy, high-throughput
597 quantitative microscopy analysis. *Molecular Microbiology* **99**, 767–777; 10.1111/mmi.13264
598 (2016).

599 37. Rueden, C. T. *et al.* ImageJ2: ImageJ for the next generation of scientific image data. *BMC
600 Bioinformatics* **18**, 529; 10.1186/s12859-017-1934-z (2017).

601 38. Jaqaman, K. *et al.* Robust single-particle tracking in live-cell time-lapse sequences. *Nature
602 Methods* **5**, 695–702; 10.1038/nmeth.1237 (2008).

603 39. Andrews, S. *FastQC: A Quality Control Tool for High Throughput Sequence Data*. Available at
604 Available online at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (Online, 2010).

605 40. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
606 *EMBnet.journal* **17**, 10–12 (2011).

607 41. Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment
608 and genotyping with HISAT2 and HISAT-genotype. *Nature Biotechnology* **37**, 907–915;
609 10.1038/s41587-019-0201-4 (2019).

610 42. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *GigaScience* **10**;
611 10.1093/gigascience/giab008 (2021).

612 43. Robinson, J. T. *et al.* Integrative genomics viewer. *Nature Biotechnology* **29**, 24–26;
613 10.1038/nbt.1754 (2011).

614 44. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
615 RNA-seq data with DESeq2. *Genome biology* **15**, 550; 10.1186/s13059-014-0550-8 (2014).

616 45. Wickham, H. *ggplot2. Elegant graphics for data analysis* (Springer, Switzerland, 2016).

617